Role of increased circulating microparticles in adverse outcomes of COVID-19 patients with diabetes

循环微粒增加对患有糖尿病的 COVID-19 患者不良后果的影响

基本信息

  • 批准号:
    10547868
  • 负责人:
  • 金额:
    $ 32.47万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-04-01 至 2024-03-31
  • 项目状态:
    已结题

项目摘要

A. Provide supporting data showing that diabetic MPs contribute to the increases in the propagation of the virus compared to non-diabetic MP. A1. Demonstrate higher number of cellular internalizations of S-protein-bound DB MPs than that of S-protein-bound normal MPs. Experiments will be conducted in microvessels developed in microfluidics. Our preliminary data showed no significant differences in ACE2 expression and ACE2-mediated MP interaction with S-protein between normal and DB MPs. The main factors that contribute to DB MP-mediated increases in virus entry are their much higher quantity and more adhesive surface due to their largely externalized phosphatidylserine (PS) than that of normal MPs. GFPtagged S-protein will be incubated with MPs isolated from normal and DB plasma and flow cytometry will be used to confirm the S-protein-bound MPs. To demonstrate the quality differences between normal and DB MPs, equal amount of S-protein-bound DB and normal MPs will be perfused into the in vitro microvessels. Confocal images will be collected to compare the internalized S-protein-bound DB MPs with that of normal MPs by quantification of GFP fluorescence. To demonstrate the role of externalized PS on DB MPs in the MP adhesion and internalization, the S-protein-bound DB MPs will be pre-coated with a lipid binding protein, Annexin V, before perfusion into microvessels. We predict that precoating of DB MPs with Annexin V will prevent the DB MP adhesion to ECs and reduce their cellular internalizations. A2. Demonstrate DB MP-mediated increases in HCoV-NL63 infection and propagation when compared to normal MPs. HCoV-NL63 (BEI Resources) will be propagated in Caco-2 cells to produce a working virus stock. Cultured ECs will be incubated with HCoV-NL63 with serial dilutions (1:10-1000) in the presence of DB and normal plasma or equal number of isolated DB and normal MPs, respectively. The incubation of HCoV-NL63 alone serves as viral infection control. To demonstrate the specific role of DB MPs in facilitating viral infection from that of other components in DB plasma such as inflammatory mediators and cytokines, cultured ECs will be incubated with HCoV-NL63 in the presence of MP-free DB plasma and the results will be compared with DB plasma containing increased MPs. For rigor, efficiency of HCoVNL63 infection will be determined using three distinct methods. Total virus will be harvested from cells and supernatant at 96 hpi and quantified by both plaque assay and 50% tissue culture infectious dose (TCID 50) assay as previously published (PMID 19014487). Infection will also be quantified using a one-step, real-time, quantitative reverse transcription PCR assay on RNA harvested from cells at 96 hpi using a commercially available kit (Liferiver). Supernatant will be collected daily to examine the release of MPs and cytokines, serving as indicators of viral infection-induced EC activation. Results will be compared among groups (3-4 replicates per group for all proposed preliminary studies). B. Provide preliminary data to support that HCoV-NL63 virus could produce the illness that is similar to SARS-CoV-2. HCoV-NL63 has been reported to cause upper respiratory tract infections in children, and also to cause pneumonia, as well as airway inflammation in K18-ACE2 mice. In this preliminary study, we will develop a hamster model of HCoVNL63 infection. Golden Syrian hamsters (8-10 weeks old, Charles River) will be used for this study. Normal and STZinduced diabetic hamsters will be intranasally inoculated with serial dilutions of HCoV-NL63 (5 x 104, 5 x 105, or 5 x 106 TCID50) in 200 μL PBS to establish the ID50 in vivo. Oral and rectal swabs will be collected every 24 hours starting 1-day post-inoculation (dpi) for up to five days. Body weight and clinical signs of illness as indicated by labored breathing, hunched posture and immobility, and temperature will be monitored twice a day. Hamsters will be euthanized on 3 and 5 dpi to harvest lungs and peripheral tissues. Remaining animals are sacrificed at 7 dpi (n = 3 per group). Hamster lungs will be assessed for histology and viral replication (measure viral RNA levels by qPCR). Cytokines will be measured in bronchoalveolar lavage and lung homogenate. Plasma will be collected for MP and cytokine analysis (details see application experimental designs C4B2). Results will be compared among groups. We predict that HCoV-NL63-infected DB hamsters have more severe respiratory inflammatory responses than HCoV-NL63-infected normal hamsters. Our previous study showed that cross-transfusion of DB plasma to normal rats caused immediate vascular inflammation in the recipient rat, indicating a role of DB MPs in mediating propagation of inflammation in the vasculature. To evaluate the specific role of DB MPs in facilitation and propagation of HCoV-NL63 infection, 40% plasma volume of a HCoV-NL63- infected normal hamster will be replaced by MP-rich and MP-free DB plasma (normal plasma as sham control) or vice versa and the viral infection-induced illness and vascular pathology will be compared between groups. In case HCoVNL63 infection alone causes very mild clinical symptoms in hamsters, the alternative is to coinfect hamster with human influenza H1N1 and HCoV-NL63. Hamster is an established animal model for the study of human influenza infection and coinfection of SRAS-CoV-2 and influenza has been shown to enhance the severity of pneumonia in hamsters. C. Provide evidence for a novel therapeutic target to alleviate the adverse outcomes of COVID-19 patients with diabetes. The focus of this application is to reveal a novel mechanism by which diabetes exacerbates the COVID-19 outcomes. The proposed mechanistic studies will lead to the identification of a novel target for therapeutic development. Our previous study showed that carotid injection of Annexin V (1 ml, 100 μg/Kg) to a DB rat reduced plasma MPs from 465 x 104/μL to 22 x 104/μL 1h after the injection. We will apply the same approach to HCoV-NL63 infected DB hamsters, and the plasma MPs and viral infection outcomes will be evaluated accordingly. The drug development is out of scope of this application. However, these preliminary studies will provide mechanistic evidence supporting the development of a Annexin V-based therapeutic product in the future studies.

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PINGNIAN HE其他文献

PINGNIAN HE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PINGNIAN HE', 18)}}的其他基金

Red blood cell released ATP in disturbed blood flow-initiated site specific vascular inflammation and atherosclerosis
红细胞在血流紊乱引发的特定部位血管炎症和动脉粥样硬化中释放 ATP
  • 批准号:
    10457975
  • 财政年份:
    2019
  • 资助金额:
    $ 32.47万
  • 项目类别:
Red blood cell released ATP in disturbed blood flow-initiated site specific vascular inflammation and atherosclerosis
红细胞在血流紊乱引发的特定部位血管炎症和动脉粥样硬化中释放 ATP
  • 批准号:
    10180296
  • 财政年份:
    2019
  • 资助金额:
    $ 32.47万
  • 项目类别:
Red blood cell released ATP in disturbed blood flow-initiated site specific vascular inflammation and atherosclerosis
红细胞在血流紊乱引发的特定部位血管炎症和动脉粥样硬化中释放 ATP
  • 批准号:
    10221039
  • 财政年份:
    2019
  • 资助金额:
    $ 32.47万
  • 项目类别:
Nitric oxide and microvessel permeability in vivo
一氧化氮和体内微血管通透性
  • 批准号:
    9258790
  • 财政年份:
    2016
  • 资助金额:
    $ 32.47万
  • 项目类别:
Microparticles and microvascular dysfunction in diabetes
糖尿病中的微粒和微血管功能障碍
  • 批准号:
    8680231
  • 财政年份:
    2013
  • 资助金额:
    $ 32.47万
  • 项目类别:
Microparticles and microvascular dysfunction in diabetes
糖尿病中的微粒和微血管功能障碍
  • 批准号:
    9120245
  • 财政年份:
    2013
  • 资助金额:
    $ 32.47万
  • 项目类别:
Microparticles and microvascular dysfunction in diabetes
糖尿病中的微粒和微血管功能障碍
  • 批准号:
    8578849
  • 财政年份:
    2013
  • 资助金额:
    $ 32.47万
  • 项目类别:
Microparticles and microvascular dysfunction in diabetes
糖尿病中的微粒和微血管功能障碍
  • 批准号:
    8996443
  • 财政年份:
    2013
  • 资助金额:
    $ 32.47万
  • 项目类别:
Nitric Oxide and Microvessel Permeability In Vivo
体内一氧化氮和微血管通透性
  • 批准号:
    7747939
  • 财政年份:
    2007
  • 资助金额:
    $ 32.47万
  • 项目类别:
Nitric Oxide and Microvessel Permeability In Vivo
体内一氧化氮和微血管通透性
  • 批准号:
    7213844
  • 财政年份:
    2007
  • 资助金额:
    $ 32.47万
  • 项目类别:

相似国自然基金

新型蝙蝠MERS簇冠状病毒HKU5的ACE2细胞受体识别及其分子机制研究
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
铁皮石斛通过肠道 ACE2 修复 Trp/GPR142 介 导“肠-胰岛 ”轴血糖调控功能的降糖机制研 究
  • 批准号:
    Y24H280055
  • 批准年份:
    2024
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
人类ACE2变构抑制剂的成药性及其抗广谱冠状病毒感染的机制研究
  • 批准号:
    82330111
  • 批准年份:
    2023
  • 资助金额:
    220 万元
  • 项目类别:
    重点项目
CAFs来源的外泌体负性调控ACE2促进肾透明细胞癌癌栓新辅助靶向耐药的机制研究
  • 批准号:
    82373169
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
新型蝙蝠MERS簇冠状病毒HKU5的ACE2受体识别及细胞入侵机制研究
  • 批准号:
    32300137
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
基于外泌体miRNAs介导细胞通讯的大豆ACE2激活肽调控血管稳态机制研究
  • 批准号:
    32302080
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
感毒清经ACE2/Ang(1-7)/MasR信号通路抑制PM2.5诱导慢性气道炎症的机制:聚焦肺泡巨噬细胞极化与“胞葬”的表型串扰
  • 批准号:
    82305171
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
刺参自溶引发机制中ACE2调控靶点的调控网络研究
  • 批准号:
    32372399
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
Spike变异对新冠病毒抗原性及ACE2种属嗜性的影响研究
  • 批准号:
    82272305
  • 批准年份:
    2022
  • 资助金额:
    52 万元
  • 项目类别:
    面上项目

相似海外基金

新型コロナウイルス感染阻害能を有する抗ACE2抗体の阻害機構に関する構造基盤解明
阐明具有抑制新型冠状病毒感染能力的抗ACE2抗体抑制机制的结构基础
  • 批准号:
    24K09338
  • 财政年份:
    2024
  • 资助金额:
    $ 32.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
ACE2のユビキチン化を介したコロナウイルス感染機構の解明と創薬への挑戦
通过ACE2泛素化阐明冠状病毒感染机制和药物发现的挑战
  • 批准号:
    22KJ2499
  • 财政年份:
    2023
  • 资助金额:
    $ 32.47万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
ACE2阻害薬およびERK経路阻害薬による慢性腎炎進展抑制効果の検証
ACE2抑制剂和ERK通路抑制剂抑制慢性肾炎进展的效果验证
  • 批准号:
    23K14982
  • 财政年份:
    2023
  • 资助金额:
    $ 32.47万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Large-scale compatibility assessments between ACE2 proteins and diverse sarbecovirus spikes
ACE2 蛋白和多种 sarbecovirus 尖峰之间的大规模兼容性评估
  • 批准号:
    10722852
  • 财政年份:
    2023
  • 资助金额:
    $ 32.47万
  • 项目类别:
一次線毛とコロナウイルス感染におけるACE2の役割の解明
阐明 ACE2 在原发菌毛和冠状病毒感染中的作用
  • 批准号:
    22KF0004
  • 财政年份:
    2023
  • 资助金额:
    $ 32.47万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
The regulatory roles of ACE2 and its interaction with Nrf2 in arsenic-induced endothelial dysfunction in experimental and epidemiological studies
实验和流行病学研究中 ACE2 的调节作用及其与 Nrf2 的相互作用在砷诱导的内皮功能障碍中的作用
  • 批准号:
    23K16310
  • 财政年份:
    2023
  • 资助金额:
    $ 32.47万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Role of ACE2 in the mechanism of intestinal regeneration
ACE2在肠道再生机制中的作用
  • 批准号:
    23K15078
  • 财政年份:
    2023
  • 资助金额:
    $ 32.47万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Research and development of a novel pediatric anti-obesity medicine via ACE2 activation in DIZE
通过 DIZE 中 ACE2 激活研发新型儿科抗肥胖药物
  • 批准号:
    23K15417
  • 财政年份:
    2023
  • 资助金额:
    $ 32.47万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Lung delivery of novel ACE2 variants for COVID-19
针对 COVID-19 的新型 ACE2 变体的肺部输送
  • 批准号:
    10483042
  • 财政年份:
    2022
  • 资助金额:
    $ 32.47万
  • 项目类别:
ACE2 on gut barrier dysfunction and BRB disruption
ACE2 对肠道屏障功能障碍和 BRB 破坏的影响
  • 批准号:
    10535485
  • 财政年份:
    2022
  • 资助金额:
    $ 32.47万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了